DK1919878T3 - Pyridazinonderivater som thyroidhormonreceptoragonister - Google Patents

Pyridazinonderivater som thyroidhormonreceptoragonister

Info

Publication number
DK1919878T3
DK1919878T3 DK06792493.6T DK06792493T DK1919878T3 DK 1919878 T3 DK1919878 T3 DK 1919878T3 DK 06792493 T DK06792493 T DK 06792493T DK 1919878 T3 DK1919878 T3 DK 1919878T3
Authority
DK
Denmark
Prior art keywords
receptor agonists
hormone receptor
thyroid hormone
pyridazine derivatives
pyridazine
Prior art date
Application number
DK06792493.6T
Other languages
English (en)
Inventor
Nancy-Ellen Haynes
Denis John Kertesz
Sherrie Lynn Pietranico-Cole
Yimin Qian
Nathan Robert Scott
Sung-Sau So
Kshitij Chhabilbhai Thakkar
Jefferson Wright Tilley
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1919878T3 publication Critical patent/DK1919878T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/18—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK06792493.6T 2005-07-21 2006-07-11 Pyridazinonderivater som thyroidhormonreceptoragonister DK1919878T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70121505P 2005-07-21 2005-07-21
PCT/EP2006/064093 WO2007009913A1 (en) 2005-07-21 2006-07-11 Pyridazinone derivatives as thyroid hormone receptor agonists

Publications (1)

Publication Number Publication Date
DK1919878T3 true DK1919878T3 (da) 2010-10-25

Family

ID=37114368

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06792493.6T DK1919878T3 (da) 2005-07-21 2006-07-11 Pyridazinonderivater som thyroidhormonreceptoragonister

Country Status (32)

Country Link
US (3) US7452882B2 (da)
EP (1) EP1919878B1 (da)
JP (1) JP5000649B2 (da)
KR (1) KR100965006B1 (da)
CN (1) CN101228135B (da)
AR (1) AR054848A1 (da)
AT (1) ATE480524T1 (da)
AU (1) AU2006271721C1 (da)
BR (1) BRPI0613754B8 (da)
CA (1) CA2614529C (da)
CR (1) CR9644A (da)
CY (1) CY1110929T1 (da)
DE (1) DE602006016821D1 (da)
DK (1) DK1919878T3 (da)
EC (1) ECSP088120A (da)
ES (1) ES2349131T3 (da)
HK (1) HK1115129A1 (da)
HR (1) HRP20100633T1 (da)
IL (1) IL188476A (da)
MA (1) MA29731B1 (da)
MX (1) MX2008000818A (da)
MY (1) MY142861A (da)
NO (1) NO340679B1 (da)
NZ (1) NZ565190A (da)
PL (1) PL1919878T3 (da)
PT (1) PT1919878E (da)
RS (1) RS51639B (da)
RU (1) RU2379295C2 (da)
TW (1) TWI330636B (da)
UA (1) UA88104C2 (da)
WO (1) WO2007009913A1 (da)
ZA (1) ZA200800405B (da)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128058A2 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
RU2422450C2 (ru) 2003-11-19 2011-06-27 Метабазис Терапеутикс, Инк. Новые фосфорсодержащие тиромиметики
EP1604988A1 (en) * 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
PT1919878E (pt) 2005-07-21 2010-11-02 Hoffmann La Roche Derivados de piridazinona como agonistas do receptor da hormona da tiróide
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
JPWO2008133141A1 (ja) * 2007-04-24 2010-07-22 東洋紡績株式会社 オスモチン組換えタンパク質およびその製造方法、並びにその利用
PL2061766T3 (pl) 2007-06-06 2011-02-28 Torrent Pharmaceuticals Ltd Nowe związki
US8076334B2 (en) * 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
NZ585395A (en) 2007-11-15 2012-03-30 Angeletti P Ist Richerche Bio Pyridazinone derivatives as parp inhibitors
KR100981781B1 (ko) 2008-02-29 2010-09-10 재단법인 한국원자력의학원 방사선 치료용 콜리메이터 장치 및 그 장치를 이용한방사선 치료장치
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CA2758894C (en) 2009-04-20 2013-09-10 Mitsubishi Tanabe Pharma Corporation Novel thyroid hormone .beta. receptor agonist
US8785608B2 (en) 2009-08-26 2014-07-22 Sanofi Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
JP5847533B2 (ja) * 2010-10-19 2016-01-27 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
BR112015005891A2 (pt) * 2012-09-17 2017-08-08 F Hoffmann La Roche Ltd método de sintetizar análogos do hormônio da tireoide e polimorfos destes
CN105272927A (zh) * 2015-11-17 2016-01-27 华中药业股份有限公司 一种制备氯氮卓的新方法
KR20190109387A (ko) 2016-10-18 2019-09-25 마드리갈 파마슈티칼스, 인크. Thr-베타 아고니스트로 간 질환 또는 지질 질환을 치료하는 방법
AU2017363206A1 (en) 2016-11-21 2019-06-13 Viking Therapeutics, Inc. Method of treating glycogen storage disease
EA201992703A1 (ru) 2017-06-05 2020-04-15 Вайкинг Терапьютикс, Инк. Композиции для лечения фиброза
US20210154370A1 (en) 2017-09-14 2021-05-27 Riken Method for producing retinal tissues
US11485729B2 (en) 2018-01-23 2022-11-01 Shenzhen Targetrx, Inc. Substituted pyridazinone compound
MX2020010928A (es) 2018-04-16 2020-11-06 Ioulia Tseti Una composicion farmaceutica en polvo seco para inhalacion que comprende una hormona tiroidea.
BR112020022146A2 (pt) 2018-06-12 2021-01-26 Fronthera U.S. Pharmaceuticals Llc compostos da fórmula e composição farmacêutica
US20210292304A1 (en) * 2018-06-22 2021-09-23 Hinova Pharmaceuticals Inc. Deuterated mgl-3196 compound and use thereof
TW202019914A (zh) * 2018-07-02 2020-06-01 美商瑪德瑞高製藥公司 ２-（３，５-二氯-４-（（５-異丙基-６-側氧基-１，６-二氫噠嗪-３-基）氧）苯基）-３，５-二側氧基-２，３，４，５-四氫-１，２，４-三嗪-６-腈之固體型式
EP3840755A4 (en) * 2018-08-24 2022-04-20 Terns, Inc. THYROID HORMONE BETA RECEPTOR AGONIST COMPOUNDS
JP2022500366A (ja) * 2018-09-06 2022-01-04 ガルメド リサーチ アンド ディベロップメント リミテッド 肝疾患治療のための併用療法
US11203587B2 (en) 2018-10-12 2021-12-21 Terns, Inc. Thyroid hormone receptor beta agonist compounds
US20210355110A1 (en) * 2018-10-12 2021-11-18 InventisBio Co., Ltd. Thyroid hormone receptor agonists
CN111320609A (zh) * 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN111592528A (zh) * 2019-02-20 2020-08-28 苏州泽璟生物制药股份有限公司 氘代的哒嗪酮及其衍生物和药物组合物
CN113474335A (zh) * 2019-02-21 2021-10-01 南京瑞捷医药科技有限公司 新型化合物及其作为甲状腺激素受体激动剂的用途
AU2020234344A1 (en) 2019-03-13 2021-10-07 Riken Method for evaluating quality of transplant neural retina, and transplant neural retina sheet
AU2020267576A1 (en) * 2019-05-08 2021-12-09 Aligos Therapeutics, Inc. Modulators of THR-β and methods of use thereof
CN111909137B (zh) * 2019-05-10 2023-05-30 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
CN114174282A (zh) * 2019-05-29 2022-03-11 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
GB2603330B (en) 2019-08-19 2023-08-09 Hepagene Therapeutics Hk Ltd Heterocyclic THR-B receptor agonist compound and preparation method and use therefor
CN112409340B (zh) * 2019-08-21 2022-03-18 海创药业股份有限公司 卤素取代的苯醚类化合物及其用途
CA3154488A1 (en) * 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CN112442013B (zh) * 2019-09-04 2022-07-26 广东东阳光药业有限公司 一种作为甲状腺激素β受体激动剂的化合物及其用途
JP2022548250A (ja) * 2019-09-12 2022-11-17 ターンズ・ファーマシューティカルズ・インコーポレイテッド 甲状腺ホルモン受容体ベータアゴニスト化合物
EP4036090A4 (en) * 2019-09-24 2023-11-15 Sunshine Lake Pharma Co., Ltd. CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF
CN112707892A (zh) * 2019-10-24 2021-04-27 苏州泽璟生物制药股份有限公司 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物
WO2021104288A1 (zh) 2019-11-26 2021-06-03 昆药集团股份有限公司 1，2，4-三嗪-3，5-二酮类化合物及其制备方法和应用
CN114787153A (zh) * 2019-12-26 2022-07-22 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
CN113045551A (zh) * 2019-12-27 2021-06-29 广东东阳光药业有限公司 一种作为甲状腺激素β受体激动剂的化合物及其用途
CN115244037A (zh) 2020-01-13 2022-10-25 上海诚益生物科技有限公司 作为甲状腺激素受体激动剂的被取代的三嗪酮类
CN113278013B (zh) * 2020-02-20 2022-09-23 昆药集团股份有限公司 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用
CN113698388B (zh) * 2020-05-20 2022-11-22 江苏恒瑞医药股份有限公司 6-氧代-1,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
CA3185710A1 (en) 2020-06-02 2021-12-09 Chengdu Kanghong Pharmaceutical Co., Ltd. Novel thyroid hormone .beta. receptor agonist
US20230339911A1 (en) * 2020-08-27 2023-10-26 InventisBio Co., Ltd. Pyridazinone compounds
WO2022053028A1 (zh) * 2020-09-10 2022-03-17 南京明德新药研发有限公司 1,2,4-三嗪-3,5(2h,4h)-二酮类化合物及其应用
KR20230066408A (ko) * 2020-09-10 2023-05-15 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 레스메티롬의 결정형, 이의 제조 방법 및 이의 용도
WO2022054925A1 (ja) 2020-09-11 2022-03-17 国立研究開発法人理化学研究所 神経網膜を含む細胞凝集体とマトリクスとを含む複合体及びその製造方法
CA3194364A1 (en) 2020-09-11 2022-03-17 Sumitomo Pharma Co., Ltd. Medium for tissue for transplantation
WO2022068915A1 (zh) * 2020-09-30 2022-04-07 江苏恒瑞医药股份有限公司 6-氧代-1,6-二氢哒嗪类衍生物、其制备方法及其在医药上的应用
EP4204419A1 (en) 2020-10-19 2023-07-05 Teva Pharmaceuticals International GmbH Solid state forms of resmetirom
KR20230123928A (ko) * 2020-11-06 2023-08-24 알리고스 테라퓨틱스 인코포레이티드 갑상선 호르몬 수용체 베타(tr-베타) 작용제로서의 비사이클릭 피리다지논
CN112645936B (zh) 2020-12-17 2022-03-01 山东第一医科大学(山东省医学科学院) 取代的哒嗪酮类化合物及其用途
CN114685450A (zh) * 2020-12-30 2022-07-01 昆药集团股份有限公司 2-吡啶酮类衍生物及其制备方法和在医药上的应用
CN114907327A (zh) * 2021-02-10 2022-08-16 杭州领业医药科技有限公司 Resmetirom的晶型及其制备方法和用途
CN115073429A (zh) * 2021-03-15 2022-09-20 昆药集团股份有限公司 一种1，2，4-三嗪-3，5-二酮类化合物的盐型、晶型及其制备方法
WO2024084491A1 (en) * 2022-10-21 2024-04-25 Mehta Nilesh Vipinchandra Process for synthesis of res metirom and its intermediates thereof
CN115650928B (zh) * 2022-12-28 2023-03-31 凯思凯旭(上海)医药科技有限公司 一种多环类甲状腺激素β受体激动剂及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582842A (en) 1981-02-25 1986-04-15 Merck & Co., Inc. Anti-asthmatic 6H-dibenz-[b,e] [1,4]oxathiepin derivatives, compositions, and method of use therefor
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US5284971A (en) * 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
EP0728482A3 (en) 1995-02-10 1999-10-20 Smithkline Beecham Corporation Use of hcp specific compounds to enhance erythropoiesis
JP2989015B2 (ja) 1995-06-06 1999-12-13 ファイザー・インコーポレーテッド ２，４−ジクロロピリジン類を２−アリールオキシ−４−クロロピリジン類へ変換する方法
AU6480796A (en) 1995-06-30 1997-02-05 Smithkline Beecham Corporation Use of stat 6 sh2 domain specific compounds to treat allergic reactions
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
GB9713739D0 (en) * 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
AR023659A1 (es) 1998-09-18 2002-09-04 Vertex Pharma Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
JP3699355B2 (ja) * 1999-03-01 2005-09-28 ファイザー・プロダクツ・インク 甲状腺受容体リガンドとしてのオキサミド酸類及びその誘導体類
EP1347959A1 (de) * 2000-12-27 2003-10-01 Bayer Aktiengesellschaft Indol-derivate
US7144909B2 (en) * 2001-02-08 2006-12-05 Karo Bio Ab Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands
ATE297902T1 (de) * 2001-02-28 2005-07-15 Pfizer Prod Inc Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren
RU2422450C2 (ru) 2003-11-19 2011-06-27 Метабазис Терапеутикс, Инк. Новые фосфорсодержащие тиромиметики
EP1730120A1 (en) * 2004-03-23 2006-12-13 F.Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
PT1919878E (pt) 2005-07-21 2010-11-02 Hoffmann La Roche Derivados de piridazinona como agonistas do receptor da hormona da tiróide

Also Published As

Publication number Publication date
KR20080019297A (ko) 2008-03-03
US7452882B2 (en) 2008-11-18
CA2614529A1 (en) 2007-01-25
US20070032494A1 (en) 2007-02-08
US7807674B2 (en) 2010-10-05
CY1110929T1 (el) 2015-06-10
IL188476A (en) 2011-10-31
PL1919878T3 (pl) 2011-03-31
DE602006016821D1 (de) 2010-10-21
BRPI0613754A2 (pt) 2011-02-08
EP1919878B1 (en) 2010-09-08
RS51639B (en) 2011-10-31
ZA200800405B (en) 2008-12-31
AU2006271721B2 (en) 2010-06-17
BRPI0613754B8 (pt) 2021-05-25
JP5000649B2 (ja) 2012-08-15
AU2006271721A1 (en) 2007-01-25
RU2008106058A (ru) 2009-08-27
CR9644A (es) 2008-02-20
KR100965006B1 (ko) 2010-06-21
AU2006271721C1 (en) 2013-09-19
ES2349131T3 (es) 2010-12-28
MA29731B1 (fr) 2008-09-01
IL188476A0 (en) 2008-04-13
AR054848A1 (es) 2007-07-18
TW200745052A (en) 2007-12-16
US20090005383A1 (en) 2009-01-01
UA88104C2 (ru) 2009-09-10
MY142861A (en) 2011-01-14
TWI330636B (en) 2010-09-21
BRPI0613754B1 (pt) 2021-03-16
EP1919878A1 (en) 2008-05-14
JP2009501759A (ja) 2009-01-22
NO20080058L (no) 2008-04-18
RU2379295C2 (ru) 2010-01-20
CA2614529C (en) 2011-06-28
USRE46024E1 (en) 2016-06-07
CN101228135B (zh) 2011-08-31
ECSP088120A (es) 2008-02-20
NO340679B1 (no) 2017-05-29
NZ565190A (en) 2010-02-26
ATE480524T1 (de) 2010-09-15
PT1919878E (pt) 2010-11-02
MX2008000818A (es) 2008-03-18
WO2007009913A1 (en) 2007-01-25
HK1115129A1 (en) 2008-11-21
HRP20100633T1 (hr) 2011-01-31
CN101228135A (zh) 2008-07-23

Similar Documents

Publication Publication Date Title
DK1919878T3 (da) Pyridazinonderivater som thyroidhormonreceptoragonister
ATE549350T1 (de) Neuropeptid-2-rezeptor-agonisten
DK1863474T3 (da) Hidtil ukendte thiophenderivater som sphingosin-1-phosphat-1-receptoragonister
DK2206710T3 (da) Indolderivater som s1p1-receptor agonister
DK1863818T3 (da) Acetylenyl-pyrazolo-pyrimidinderivater som mglur2-antagonister
IL188550A0 (en) Heterocyclic compounds as agonists for the thyroid receptor
DK1868999T3 (da) Pyridin-3-carboxamidderivater som omvendte CB1-agonister
ATE504559T1 (de) Arylanilinderivate als agonisten des beta2- adrenergen rezeptors
DK1841768T3 (da) Purinderivater virkende som A2A-receptoragonister
DK1856110T3 (da) Oxyindol derivater som 5HT4-receptor agonister
DK2066669T3 (da) Adenosinderivater som A2A-receptoragonister
DK1904477T3 (da) Indol-3-carbonyl-spiro-piperodom-derivater som V1A-receptorantagonister
DE602006020447D1 (de) Niacin-rezeptoragonisten, zusammensetzungen mit de
HK1099019A1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
DK1989196T3 (da) Piperidinoylpyrrolidiner som melanocortin-type 4-receptoragonister
IL177059A0 (en) Indazole-carboxamide compounds as 5-ht4 receptor agonists
ATE520670T1 (de) Pyridazinderivate
DK2069322T3 (da) THIOPHENDERIVATER SOM S1P1/EDG1-receptoragonister
ATE444748T1 (de) 1-ä(3-hydroxy-adamant-1-ylamino)-acetylü- pyrrolidin-2(s)-carbonitril-formulierung mit modifizierter freisetzung
DK2029549T3 (da) Phenyl-pyrazol-derivater som ikke-steroide glucocoricoid-receptorligander
DK1755593T3 (da) Naphtalenderivater der er nyttige som histamin-3-receptorligander
DK1740583T3 (da) Oxadiazolon-derivater som ppar-delta-agonister
HK1110980A1 (en) Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
DK1749001T3 (da) 3-piperidinylisochroman-5-ol som dopaminagonister
BRPI0612471A2 (pt) novos compostos como agonistas glp-1